Antineoplastic Agents (Antineoplastics)

Subscribe to Selected New Research on Antineoplastic Agents

2332 relevant articles (140 outcomes, 229 trials/studies) found for this Bio-Agent

Description: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Also Known As:

Antineoplastics; Antineoplastic Drugs; Antitumor Agents; Antitumor Drugs; Agents, Antineoplastic; Agents, Antitumor; Drugs, Antineoplastic; Drugs, Antitumor

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 50

Therapeutic Uses: 189

Antineoplastic Agents: 2332

Angiogenesis Inhibitors: 662

Antimitotic Agents: 165

Anticarcinogenic Agents: 80

Antineoplastic Antibiotics: 26

Alkylating Antineoplastic Agents: 8

Hormonal Antineoplastic Agents: 1

Phytogenic Antineoplastic Agents: 1

Antineoplastic Antimetabolites

Myeloablative Agonists

Experts

1.	Vahid, Bobbak: 2 articles (05/2008 - 02/2008)
2.	Marik, Paul E: 2 articles (05/2008 - 02/2008)
3.	Zhou, Yu-Dong: 2 articles (01/2007 - 05/2004)
4.	Nagle, Dale G: 2 articles (01/2007 - 05/2004)
5.	Krasil'nikov, M A: 2 articles (10/2006 - 03/2004)
6.	De, A U: 2 articles (05/2001 - 01/2001)
7.	Koch, T H: 2 articles (01/2001 - 06/2000)
8.	Taatjes, D J: 2 articles (01/2001 - 06/2000)
9.	Yuan, Renxu: 1 article (10/2008)
10.	Liang, Biling: 1 article (10/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2005 - "The elucidation of CRC biology is paving the way to the development of molecularly targeted strategies, and results from controlled clinical trials have already demonstrated that some agents targeting tumor-specific molecules can significantly improve the therapeutic efficacy of conventional antineoplastic drugs" 07/01/1991 - "Clinical predictability of preclinical test for antitumor agents has not been significantly improved even after the use of a human tumor/nude mouse model" 01/01/1986 - "Major advances in the therapy of metastatic disease are considered unlikely in the next few years, and progress will stem from improved use of existing agents in refined combination therapy protocols in which greater attention is given to the duration, frequency, and sequence of therapy with different agents to limit emergence of tumor cell variants resistant to one or more antineoplastic agents" 10/01/1984 - "These data suggest that as more antineoplastic agents become available, and as mean survival times increase, knowledge of the relative in vitro sensitivity of a patient's neoplasm to a specific antineoplastic drug (i.e., dose required for growth inhibition) as a function of its mutagenic index might be useful for prediction of clinical remission, as well as the risk of secondary neoplasm induction." 03/15/2002 - "Murine models of spontaneous cancer in which tumor formation is dependent on defined genetic alterations provide a powerful test system for evaluating the therapeutic efficacy of pathway-specific antineoplastics" Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 10/01/1996 - "Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer" 01/01/1989 - "Since it seems most unlikely that a new wonder drug for breast cancer will emerge in the next few years, then it is to our existing armamentarium of antineoplastic agents that we will have to turn for improved therapeutic results" 02/20/1983 - "Correlation between antitumor effects against human mammary carcinoma (MX-1) in nude mice and clinical efficacy of human breast cancer in thirty-four antitumor agents]" 01/01/2001 - "The aim of this study was to investigate the efficacy and toxicity of the combination of these two antitumor drugs in patients with metastatic breast cancer who had been previously treated with anthracycline-containing regimens" 07/03/1998 - "This study was part of a program correlating the biological activity and molecular structure of antitumor agents; the effect of these curcuminoids and cyclocurcumin (Cyclocur) was examined on the proliferation of MCF-7 human breast tumor cells" Order ALL the reference details at left...
3.	Leukemia 01/01/2005 - "Therefore, the study of this form of leukemia appears also of interest for a better understanding of the action of HDAC inhibitors, potential antitumor drugs that are at the early stages of clinical studies." 08/30/1988 - "Here we present a study in which the MTT assay has been adapted to assess the effect of antineoplastic drugs on lymphoblasts of children with leukemia." 09/01/1982 - "The study of cell kinetics may provide benefits to know the effect of antitumor drugs during the treatment of human leukemia." 09/01/1965 - "Leukemia P 1534 as an experimental model for the study of antineoplastic drugs]" 12/01/2003 - "Despite the remarkable progress achieved in the treatment of leukemias over the last several years, many problems (multidrug resistance [MDR], cellular heterogeneity, heterogeneous molecular abnormalities, karyotypic instability, and lack of selective action of antineoplastic agents) still remain" Order ALL the reference details at left...
4.	Small Cell Carcinoma (Small Cell Lung Cancer) 05/01/1997 - "In the present study, clonogenic assays were used to examine the cytotoxic effects when PA was combined with other antineoplastic agents in A549 human non-small cell lung cancer cells in vitro" 02/01/2006 - "Despite the emergence of several antineoplastic drugs with activity in advanced non-small cell lung cancer (NSCLC), real progress with first-line therapy has been limited in the last decade" 10/15/2000 - "Non-small-cell lung cancer (NSCLC) cells are characterised by resistance to the toxic impact of antineoplastic drugs both in vivo and in vitro" 01/01/2003 - "BACKGROUND: The role of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is still controversial, but the recent development of a number of active antineoplastic agents has created new possibilities for disease management" 07/01/2000 - "Docetaxel, a semisynthetic member of the taxoid class of antineoplastic agents, is effective in the treatment of patients with locally advanced and metastatic non-small cell lung cancer (NSCLC)" Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 04/01/1985 - "The stability of the cell-killing efficacy of 10 antitumor drugs stored at different temperatures and concentrations was evaluated on an established human colon carcinoma cell line using the colony formation technique" 12/31/1963 - "METHODOLOGICAL CRITERIA FOR THE STUDY OF THE ACTION OF CHEMOTHERAPEUTIC ANTINEOPLASTIC AGENTS IN INITIAL CARCINOMA OF THE UTERINE CERVIX.]" 10/01/2008 - "Folate-functionalized polymeric micelle as hepatic carcinoma-targeted, MRI-ultrasensitive delivery system of antitumor drugs." 07/01/2008 - "The findings are seminal for selective targeting of antineoplastic agents to the ER, which are frequently over-expressed on carcinoma of breast and uterine origin, and opens the promising possibilities for non-immunogenic, site-specific delivery of bioactive(s) to these sites." 11/01/2006 - "WIPO W000 /117143) as antitumor agents was investigated in the human colon carcinoma cell line LoVo and in the counterpart resistant derivative LoVo/MDR cell line" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Cisplatin (Platino)
3.	Antigens
4.	Doxorubicin (Adriamycin)
5.	Methotrexate (Mexate)
6.	docetaxel (Taxotere)
7.	Cytokines
8.	Ricin
9.	Tegafur
10.	Daunorubicin (Cerubidine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Aftercare (After-Treatment)
5.	Cryotherapy (Therapy, Cold)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18510 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>